Compare Stocks: BKHA, ADCT, CGEN, and WHWK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.51 +3.8%	$1.21	$0.78 ▼ $4.98	$192.14M	1.86	1.39 million shs	67,093 shs
BKHA Black Hawk Acquisition	$7.35 -5.0%	$11.93	$5.47 ▼ $23.00	$30.53M	0.02	13,320 shs	14,111 shs
CGEN Compugen	$2.09 +4.3%	$2.43	$1.43 ▼ $3.23	$197.14M	2.78	365,744 shs	52,679 shs
WHWK Whitehawk Therapeutics	$3.04 +2.4%	$4.22	$1.97 ▼ $5.49	$173.31M	0.92	321,044 shs	8,425 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-13.06%	+2.81%	+33.79%	+8.92%	-64.31%
BKHA Black Hawk Acquisition	-37.98%	-37.58%	-34.32%	-35.55%	-29.83%
CGEN Compugen	+1.01%	-6.98%	-19.35%	-14.16%	-5.21%
WHWK Whitehawk Therapeutics	-1.66%	-12.90%	-27.03%	-23.65%	+50.76%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.51 +3.8%	$1.21	$0.78 ▼ $4.98	$192.14M	1.86	1.39 million shs	67,093 shs
BKHA Black Hawk Acquisition	$7.35 -5.0%	$11.93	$5.47 ▼ $23.00	$30.53M	0.02	13,320 shs	14,111 shs
CGEN Compugen	$2.09 +4.3%	$2.43	$1.43 ▼ $3.23	$197.14M	2.78	365,744 shs	52,679 shs
WHWK Whitehawk Therapeutics	$3.04 +2.4%	$4.22	$1.97 ▼ $5.49	$173.31M	0.92	321,044 shs	8,425 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-13.06%	+2.81%	+33.79%	+8.92%	-64.31%
BKHA Black Hawk Acquisition	-37.98%	-37.58%	-34.32%	-35.55%	-29.83%
CGEN Compugen	+1.01%	-6.98%	-19.35%	-14.16%	-5.21%
WHWK Whitehawk Therapeutics	-1.66%	-12.90%	-27.03%	-23.65%	+50.76%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$5.00	232.23% Upside
BKHA Black Hawk Acquisition	1.00	Sell	N/A	N/A
CGEN Compugen	3.00	Buy	$5.00	139.81% Upside
WHWK Whitehawk Therapeutics	2.75	Moderate Buy	$8.33	174.12% Upside

Current Analyst Ratings Breakdown

Latest BKHA, ADCT, CGEN, and WHWK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	CGEN Compugen	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$4.00
9/30/2026	WHWK Whitehawk Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$9.00
9/2/2026	WHWK Whitehawk Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/17/2026	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$5.00
8/5/2026	CGEN Compugen	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D-) ➝ Hold (C-)
8/4/2026	CGEN Compugen	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
7/17/2026	ADCT ADC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
7/17/2026	BKHA Black Hawk Acquisition	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D)
7/17/2026	CGEN Compugen	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$79.58M	2.41	N/A	N/A	($1.50) per share	-1.00
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	$74.00M	2.66	$0.39 per share	5.30	$1.09 per share	1.91
WHWK Whitehawk Therapeutics	$7.14M	24.27	N/A	N/A	$2.89 per share	1.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.74%	11/10/2026 (Estimated)
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	$35.34M	$0.38	5.49	N/A	N/A	47.56%	42.57%	26.13%	11/9/2026 (Estimated)
WHWK Whitehawk Therapeutics	-$20.60M	-$1.12	N/A	N/A	N/A	N/A	-53.89%	-49.97%	N/A

Latest BKHA, ADCT, CGEN, and WHWK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/10/2026	Q3 2026	ADCT ADC Therapeutics	-$0.21	N/A	N/A	N/A	$18.69 million	N/A
11/9/2026	Q3 2026	CGEN Compugen	-$0.08	N/A	N/A	N/A	$1.29 million	N/A
10/6/2026	Q3 2026	BKHA Black Hawk Acquisition	N/A	$0.26	N/A	$0.26	N/A	N/A
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/6/2026	Q2 2026	WHWK Whitehawk Therapeutics	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A
8/3/2026	Q2 2026	CGEN Compugen	-$0.08	-$0.07	+$0.01	-$0.07	$1.29 million	$2.60 million
7/15/2026	Q2 2026	BKHA Black Hawk Acquisition	N/A	$0.02	N/A	$0.02	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	3.03	2.97
BKHA Black Hawk Acquisition	N/A	N/A	N/A
CGEN Compugen	N/A	5.72	5.72
WHWK Whitehawk Therapeutics	N/A	17.38	17.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
BKHA Black Hawk Acquisition	N/A
CGEN Compugen	12.22%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
BKHA Black Hawk Acquisition	N/A
CGEN Compugen	9.50%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	191	127.67 million	121.16 million	Optionable
BKHA Black Hawk Acquisition	2	4.15 million	N/A	N/A
CGEN Compugen	75	94.55 million	85.57 million	Optionable
WHWK Whitehawk Therapeutics	23	57.01 million	28.56 million	N/A

BKHA, ADCT, CGEN, and WHWK Headlines

Recent News About These Companies

Whitehawk Therapeutics (NASDAQ:WHWK) and Surrozen (NASDAQ:SRZN) Critical Comparison

October 14 at 3:59 AM | americanbankingnews.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokerages

October 8, 2026 | marketbeat.com

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 As A Durable ADC Target In Ovarian Cancer And Reinforces Scientific Rationale For HWK-016

October 3, 2026 | marketscreener.comM

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026

October 1, 2026 | prnewswire.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Short Interest Update

September 16, 2026 | marketbeat.com

Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Whitehawk Therapeutics: PTK7 Stability Supports ADC Development In EGFR Wild-Type NSCLC

September 14, 2026 | rttnews.com

Whitehawk data support PTK7 target for HWK-007

September 14, 2026 | grafa.comG

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

September 13, 2026 | prnewswire.com

Whitehawk Therapeutics Adds Oncology Leader to Board

September 10, 2026 | tipranks.com

Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors

September 10, 2026 | prnewswire.com

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

September 2, 2026 | prnewswire.com

What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?

August 28, 2026 | zacks.com

Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know

August 26, 2026 | zacks.com

Whitehawk Therapeutics Inc WHWK

August 14, 2026 | morningstar.comM

TD Cowen Remains a Hold on Whitehawk Therapeutics (WHWK)

August 10, 2026 | theglobeandmail.com

Whitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial Cancers

August 6, 2026 | tipranks.com

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 6, 2026 | prnewswire.com

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

July 7, 2026 | businesswire.com

10 Hot Biotech Stocks Under $5 to Buy

June 10, 2026 | insidermonkey.com

Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?

June 10, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BKHA, ADCT, CGEN, and WHWK Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.50 +0.06 (+3.79%)

As of 10:15 AM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Black Hawk Acquisition NASDAQ:BKHA

$7.35 -0.39 (-5.04%)

As of 10:14 AM Eastern

Black Hawk Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2023 and is based in Danville, California.

Compugen NASDAQ:CGEN

$2.08 +0.09 (+4.25%)

As of 10:14 AM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Whitehawk Therapeutics NASDAQ:WHWK

$3.04 +0.07 (+2.36%)

As of 10:14 AM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BKHA, ADCT, CGEN, and WHWK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BKHA, ADCT, CGEN, and WHWK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BKHA, ADCT, CGEN, and WHWK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BKHA, ADCT, CGEN, and WHWK Company Descriptions

ADC Therapeutics NYSE:ADCT

Black Hawk Acquisition NASDAQ:BKHA

Compugen NASDAQ:CGEN

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BKHA, ADCT, CGEN, and WHWK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BKHA, ADCT, CGEN, and WHWK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BKHA, ADCT, CGEN, and WHWK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BKHA, ADCT, CGEN, and WHWK Company Descriptions

ADC Therapeutics NYSE:ADCT

Black Hawk Acquisition NASDAQ:BKHA

Compugen NASDAQ:CGEN

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools